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Abstract
The 2009 Family Smoking Prevention and Tobacco Control Act (TCA) requires tobacco 
companies to disclose information about the harmful chemicals in their products to the U.S. Food 
and Drug Administration (FDA). The law requires the FDA, in turn, to communicate this 
information to the public “in a format that is understandable and not misleading to a lay person.” 
But how should the FDA comply with this requirement? What does it mean for information about 
complex chemicals to be “understandable and not misleading to a lay person”? These questions 
are not easy ones to answer. Disclosures about the amount of harmful chemicals (constituents) in 
different tobacco products may help to inform consumers, but may also conversely prompt 
consumers to reach incorrect or unsupported conclusions about products’ relative health risks.
This paper first analyzes the FDA’s legal obligation to publish tobacco constituent information so 
that it is “understandable and not misleading to a layperson.” Second, it discusses how that legal 
analysis has guided scientific research examining how members of the public interpret messages 
regarding tobacco constituents. Lastly, this paper concludes with policy recommendations for the 
FDA as it considers how to comply with the law’s constituent disclosure requirement while still 
furthering its overall objective of promoting public health.
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INTRODUCTION
Over decades, tobacco companies carefully engineered their products—cigarettes in 
particular—to be more appealing to consumers to make them start smoking and more 
addictive to make it harder to quit.1 Considerable evidence suggests that at least some of 
these product design changes also made the products more deadly.2 In response, the 2009 
Family Smoking Prevention and Tobacco Control Act (TCA) included provisions designed 
to stop tobacco companies from manipulating their products without oversight. One 
provision requires regulated tobacco companies to provide information on constituents 
(chemicals) in—and, if relevant, emitted by—their products to the U.S. Food & Drug 
Administration (FDA), which can make regulatory decisions based on that information. 
Prior to the TCA’s enactment, neither the federal government nor the public had access to 
the companies’ information about the constituents in each brand and subbrand of tobacco 
product.3
Using the information submitted by the tobacco companies, the FDA is required to establish 
and publish a list of “harmful and potentially harmful constituents [HPHCs] in each tobacco 
product [and its smoke, if applicable] by brand and by quantity in each brand and subbrand.” 
4
 This list, according to § 904(d) of the TCA, must be published “in a format that is 
understandable and not misleading to a lay person.” 5 Though not explicitly stated, the 
requirement to consider the “lay person’s” perspective appears to reflect Congress’s 
judgment that information about the presence and quantity of harmful constituents in 
tobacco products—if communicated in an understandable and non-misleading manner—
could provide consumers with important, useful information that would enable them to make 
more informed consumer choices (to the extent permitted by their tobacco product 
addiction). Such information could potentially prompt them to quit, reduce their use, or 
switch to less harmful and less risky forms of tobacco use.
To implement this requirement, the FDA sought scientific input on which tobacco 
constituents are “harmful or potentially harmful,” and in 2012 it published a list of 93 known 
HPHCs. It then issued draft guidance instructing tobacco companies to provide the FDA 
with quantity information for 20 of these HPHCs shown in Figure 1. 6 The FDA selected this 
abbreviated list of 20 because it constituted a “representative sample” of HPHCs for which 
“testing and analytic methods are well established and widely available.” 7 The FDA stated 
that it would expand the reporting requirement to cover the remaining HPHCs in the future. 
8
To date, however, the FDA has not publicly disclosed the HPHC information it has received 
from tobacco companies. 9 Instead, it has chosen, in partnership with the National Cancer 
Institute (NCI), to fund additional research on how the FDA could disclose HPHC 
information to the public in a manner that is “understandable and not misleading” and also 
useful to consumers. 10 The FDA’s major concern is that although the HPHC disclosure 
requirement is intended to help inform consumers, disclosure may mislead consumers into 
believing that there is a “lower risk [of] harm from a product that contains lower amounts of 
specific constituents or fewer overall constituents,” 11 even when no evidence supports such 
a conclusion.
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An unfounded belief that some brands or subbrands of a product are less hazardous than 
others may in turn influence consumers to switch to an alternative brand (instead of 
quitting), to smoke more, to initiate tobacco use, or to engage in other behaviors that may be 
detrimental to health. 12 This concern is not unfounded given past history with “light” and 
“low-tar” cigarettes. Starting in the 1950s, the tobacco industry made explicit and implicit 
claims that “light” or “low tar” cigarettes were less harmful alternatives for smokers, despite 
extensive internal research demonstrating that these products would not in fact reduce 
tobacco-related harms. 13 In ensuing years, many smokers switched to “light” or “low tar” 
brands of cigarettes, likely instead of quitting smoking. 14
Disclosure of constituent information could potentially be useful if it (a) is likely to 
discourage tobacco use, or (b) demonstrates the benefits of switching to a lower-risk type (as 
opposed to brand) of tobacco product, for those unwilling or unable to quit tobacco use 
entirely. 15 However, to be useful in any of these ways (and to comply with the law), any 
such communication must still be “understandable and not misleading to a lay person”—and 
it may be difficult, if not impossible, to present the reported constituent information in a 
manner that is informative yet not simultaneously confusing and misleading. Indeed, two 
advisory committees to the FDA determined in 2013 that the FDA lacked any adequate 
means of doing so. 16
In addressing this challenge, an important preliminary step is to conduct legal analysis to 
help clearly define the terms in the TCA’s phrase “understandable and not misleading to a 
lay person.” Such definitions, translated into language that is meaningful to behavioral 
scientists, can support the development of objective survey measures that correspond to the 
terms. Behavioral scientists can then use such measures to evaluate the impact of the format 
and content of potential disclosures to ensure that they increase knowledge and do not cause 
misunderstandings, both generally and among various sub-populations, including persons 
with low literacy and low numeracy. 17 Basing this work in legal analysis is critically 
important given that any FDA effort to implement the HPHC disclosure requirement could 
be challenged in court by the tobacco industry. 18 Accordingly, public health researchers 
must understand the legal parameters of § 904(d) in order to best assist the FDA in designing 
an HPHC disclosure approach that will withstand legal scrutiny.
In 2015, the FDA and NCI funded research projects to “operationalize what constitutes 
public display of HPHC information by brand and by quantity in each brand and subbrand in 
a format that is ‘understandable and not misleading’ to a lay person.” 19 One such research 
grant was awarded to the University of North Carolina (UNC). To help inform its work—as 
well as the FDA’s ultimate regulatory decisions regarding HPHC disclosures—the UNC 
researchers commissioned a legal review of what the terms “understandable,” “not 
misleading,” and “lay person” mean in the context of TCA § 904(d).
Part I of our paper summarizes the results of that legal analysis. Part II briefly outlines how 
the legal review informed the survey work of the researchers at UNC and Ohio State 
University (OSU), providing a promising model collaboration between legal experts and 
public health scientists. Finally, Part III concludes the paper by providing some policy 
considerations and recommendations relating to the HPHC disclosure requirement.
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I. WHAT IS “UNDERSTANDABLE AND NOT MISLEADING TO A LAY 
PERSON”?
“The objective of statutory interpretation is to give effect to the intent of Congress.” 20 Of 
course, as an initial matter, courts look to the plain language of the statute. In many cases, 
however, likely including this one, looking at the plain language alone is not sufficient to 
resolve all potential ambiguities. Thus, courts provide deference to administrative agencies, 
as the subject-matter experts designated by Congress, in interpreting a statute’s meaning 
when the language is unclear. Under the longstanding (though occasionally criticized) 
Chevron Test, if the words of a statute leave some ambiguity, the courts will defer to an 
agency’s interpretation, so long as it is based on a “permissible construction of the statute.” 
21
 This is true even if the agency’s interpretation of the statute is different from the “reading 
the court would have reached if the question initially had arisen in a judicial proceeding.” 22 
Thus, it is important to emphasize that when it interprets broad terms such as 
“understandable” and “misleading,” the FDA has considerable flexibility, so long as its 
interpretations are reasonable and linked to Congress’s overall goals in enacting the TCA. 23
Because statutory interpretation focuses on the intent of Congress, one traditional tool of 
statutory interpretation is the examination of legislative history—contemporaneous 
statements in floor debates, committee reports, hearing testimony, etc. by members of 
Congress about a statute’s meaning. The statutory history, as well as the language of the 
TCA itself, makes clear that Congress’s overriding goal in enacting the TCA was to reduce 
the death and disease caused by tobacco products. 24 Accordingly, FDA’s actions to 
implement any part of the TCA should reflect this primary goal—at least where, as with § 
904(d), no specific text directs otherwise. 25
Section 904(d) is only one small part of a much broader piece of legislation, and no 
legislative history specifically addresses this provision. However, it is notable that in the 
introduction to the TCA, Congress—in addition to mentioning its overarching goal of 
“address[ing] the public health crisis created by the actions of the tobacco industry” 26—also 
suggested that its additional goals included “ensur[ing] that consumers are better informed” 
27
 and “promot[ing] understanding of the impact of the product on health.” 28 Thus, in 
interpreting the meaning of § 904(d), it is reasonable to read that provision in light of these 
additional general purposes as well, which relate to both the perspective of individual 
consumers (including both current tobacco users and potential future users, including youth) 
and to the population-level viewpoint of public health. As the TCA emphasized throughout 
the TCA (though not specifically in § 904), Congress also instructed the FDA to be sensitive 
to the differential effects that policy interventions may have on different segments of the 
population. 29
Another tool of statutory interpretation is to examine how identical or similar phrases in 
other statutes have been interpreted and applied. 30 The § 904(d) phrase, “understandable 
and not misleading to a lay person” does not appear anywhere else in the U.S. Code. 31 As 
discussed below, however, component terms of the § 904(d) phrase do appear in other 
contexts, which may provide some interpretive clues.
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A final relevant interpretive tool is the legal maxim noscitur a sociis, the principle that “a 
word may be known by the company it keeps.” 32 That is, the terms in a phrase (particularly 
when the conjunctive “and” is used) inform the meaning of the other words in that phrase. 
Each word is presumed to have its own distinct meaning that adds something additional to 
the phrase, but the terms are also expected to relate logically to one another. In this context, 
“understandable” and “not misleading” likely overlap to some extent, but their placement by 
Congress in the same phrase suggests that Congress intended them to establish separate, 
distinct requirements.
With these general principles and background in mind, the following sub-sections analyze 
the meaning of the terms “understandable,” “not misleading,” and “lay person” as the TCA 
uses them.
A. “Understandable”
“Understandable” is an ambiguous term not so much because it is unclear what 
“understandable” means, but because what must be understood and the required depth of 
understanding are uncertain. For example, what does it mean that someone “understands” 
that a certain cigarette brand’s smoke contains 100 μg of acrolein per cigarette? Is it enough 
that he or she can repeat that fact, or must there be a deeper level of comprehension? Black’s 
Law Dictionary—the definitive legal dictionary—defines “understand” as “to apprehend the 
meaning of; to know,” suggesting that the ability to simply repeat a fact does not, by itself, 
necessarily reflect understanding.33 But what else must a person know to understand that 
fact about a specific brand’s acrolein levels? How much acrolein a “typical” cigarette’s 
smoke contains? What a μg is? What impacts acrolein has on health, and the relative 
likelihood of those impacts? The extent to which acrolein is absorbed by the lungs when 
inhaled in smoke? What a “safe” level of exposure would be? What he or she should do with 
this information? 34
FDA regulations in non-tobacco contexts also suggest that the term “understandable” 
implies a deeper level of comprehension. For example, in implementing the general 
requirement that labels on medical devices must be “understood by the ordinary individual,” 
35
 FDA requires the labeling for tampons not only to disclose that the use of tampons can 
cause toxic shock syndrome, and explain what that is, but also to include information about 
the extent of the risk of toxic shock syndrome, the common warning signs for the disease, 
what to do if its warning signs appear, and how to reduce the chance of the disease 
occurring. 36 These regulations suggest that ensuring that a disclosure is “understood” 
requires providing information to consumers about not only the harms and risks related to 
the disclosed information, but also about how to reduce and address them. 37
Another relevant FDA example is 21 U.S.C. § 343(H), enacted as part of the Patient 
Protection and Affordable Care Act, which requires chain restaurants to post calorie content 
information on menus. In addition to the calorie disclosure, the law requires “a succinct 
statement concerning suggested daily caloric intake … designed to enable the public to 
understand, in the context of a total daily diet, the significance of the caloric information that 
is provided on the menu.” 38 The FDA rule implementing this requirement listed the 
following principles that should guide the development of such a statement:
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1. The succinct statement should be in plain language that consumers can 
understand;
2. The total caloric value should be framed appropriately so that it is not viewed as 
a recommendation for daily intake for every consumer; and
3. The succinct statement should inform consumers that individual needs vary. 39
This statutory scheme is different than the § 904(d) HPHC disclosure requirements, but it 
nonetheless highlights a few important concepts that may be relevant to defining 
“understandable.” First, to be understandable, the information must be presented in “plain 
language” and avoid jargon or complex vocabulary. 40 In the context of work by federal 
agencies, “plain language” has a specific technical meaning that includes the use of words 
and sentences that are easily understood by people with low educational attainment. 41 
Second, for information to be understandable, consumers must have a sense of what the 
information means for them. And third, consumers must recognize that not all people have 
the same needs (or risks). 42
The three principles in the calorie disclosure regulations are important elements of what 
“understandable” means, but it is critical to note that they (especially the latter two 
principles) may be much more difficult to apply in the context of tobacco regulation. In 
comparison to calorie data, HPHC data are likely much tougher to understand and interpret. 
The number of calories in a donut, for example, can be calculated with some precision, and 
the calories consumed will be the same regardless of who eats it. And consumers likely have 
a general sense that calorie needs may vary depending on differences in body size, 
metabolism, and physical activity. By contrast, even the tobacco industry concedes that 
available methods for measuring HPHCs “do not accurately reflect the wide range of human 
smoking behavior of individual smokers such as variability in puff volume, puff duration, 
and puff frequency.” 43 And consumers are surely much less familiar with constituents such 
as crotonaldehyde and 1-aminonaphthalene than they are with calories. Thus, making the 
HPHC information “understandable” to the public poses a considerably more difficult 
challenge.
Given the major purpose of the TCA—to reduce the death, disease, and other health harms 
caused by tobacco use—one could also argue that whether any provided HPHC information 
is actually “understandable” can ultimately be determined only by examining how 
consumers change their behavior in response to receiving the information. 44 If an HPHC 
disclosure successfully increased consumer understanding of the tobacco product’s harms 
and risks and how to reduce or address them, at least some corresponding changes in 
consumer behavior would logically follow, despite consumer brand loyalties and the 
addictive power of tobacco use. Accordingly, as the American Cancer Society Cancer Action 
Network and other public health groups have suggested, before mandating any specific 
HPHC disclosures the FDA must, at minimum, be satisfied that they will “more likely than 
not result in changes in consumer behavior that, on balance, have a positive impact on public 
health.” 45
Although the tampon regulation does not suggest that behavioral change (or anticipated 
behavioral change) should be a mechanism for evaluating “understanding,” that is likely 
Berman et al. Page 6
Food Drug Law J. Author manuscript; available in PMC 2018 February 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
because the tampon context is very different from that of tobacco product regulation. In 
approving tampons for sale in the United States, the FDA determined that they were “safe 
and effective” for their intended purposes—i.e., that the toxic shock risks they presented 
users were not substantial enough to justify prohibiting potential users from choosing to use 
tampons instead of available alternatives (so long as adequate warnings were provided). 
Accordingly, when issuing the tampon regulation, FDA stated repeatedly that only purpose 
was “to provide adequate information to women so that they can make informed decisions 
about whether and how to use tampons.” 46 Influencing what product choices the women 
actually made was not a policy goal of the agency. 47 In sharp contrast, tobacco products are 
not “safe and effective” under any definition. 48 Although the Tobacco Control Act 
references “ensur[ing] that consumers are better informed,” it is not agnostic as to what 
product-use choices consumers should make. The Tobacco Control Act is clear the FDA 
should “promote cessation to reduce disease risk and the social costs associated with 
tobacco-related disease,” 49 and that its regulatory interventions “should target all smokers 
to help them quit completely.” 50 Thus, the unique nature of tobacco products—which, 
unlike all other FDA-regulated products, are inherently lethal without offering “the 
possibility of therapeutic benefit” 51—suggests that FDA must interpret the term 
“understandable” more comprehensively in the tobacco context.
B. “Misleading”
The Food, Drug, and Cosmetic Act (FDCA) —the FDA’s general governance statute—
provides extensive general guidance on the meaning of the term “misleading,” especially in 
prohibiting “misleading” labeling or advertising. In determining whether labeling or 
advertising is misleading, Congress instructed the FDA to consider
not only representations made or suggested by [a] statement, word, design, device, 
or any combination thereof, but also the extent to which the labeling or advertising 
fails to reveal facts material in the light of such representations or material with 
respect to consequences which may result from the use of the article to which the 
labeling or advertising relates … under such conditions of use as are customary or 
usual. 52
In other words, “misleading” is not limited to falsehoods, but also includes making 
affirmatively or implicitly misleading statements, as well as the failure to provide relevant 
information necessary to put the information or risks into context.
Regulations applying this requirement to prescription drug advertisements provide some 
examples of how accurate statements can be presented in ways that still mislead people to 
reach inaccurate conclusions:
• “Present[ing] information from a study in a way that implies that the study 
represents larger or more general experience with the drug than it actually does”;
• “Us[ing] a quote or paraphrase out of context to convey a false or misleading 
idea”; and
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• “Us[ing] tables or graphs to distort or misrepresent the relationships, trends, 
differences, or changes among the variables or products studied [such as by 
failing to label the axes].” 53
In a recent federal court case from Florida, the court ruled that a label reading “100% 
Cranberry Pomegranate Flavored Juice Blend” was likely “misleading” in violation of the 
FDCA because, even though the drink was in fact 100% juice, only a small percentage of the 
juice was cranberry juice or pomegranate juice. Although everything on the label was 
technically true, it created a misleading impression that all of the juice in the drink was 
cranberry or pomegranate. 54 This ruling reinforces the general point that even 100% 
factually accurate communications can be “misleading” if incomplete or not situated in 
appropriate context. 55
Section § 904(d) is intended to provide useful information to consumers regarding the 
amounts of HPHCs in different brands and subbrands of different types of tobacco products 
so that they can better understand how harmful tobacco use is and make related behavior 
changes to reduce the health risks and harms they face. At the same time, there is a well-
founded concern (and a distinct statutory requirement) that consumers not be misled by the 
FDA’s disclosure of the HPHC information into taking actions they mistakenly think will 
reduce risks to their health, especially if those actions will actually increase their harms and 
risks. 56
To use the previous acrolein example, disclosures regarding the amount of acrolein in a 
tobacco product could increase consumer understanding of the harms and risks caused by 
the acrolein, thereby prompting efforts by consumers to reduce acrolein intake. But unless 
additional information was also provided about other tobacco-related risks unconnected to 
acrolein, consumers could be misled into taking actions that reduced their acrolein-related 
risks but either did not have any impact at all on their overall risk levels or actually increased 
them. For instance, some consumers might switch from their current brand with very high 
acrolein levels to a cigarette brand with substantially less acrolein without realizing that such 
a switch would have little or no impact on the overall health risks caused by their continued 
smoking. While their acrolein-induced health risks might decline, their overall smoking-
related harms and risks might not because of the many other HPHCs in their new cigarette 
brand. More troublingly, smokers who had previously planned to quit all tobacco use could 
similarly be misled into switching to a different brand or different tobacco product with little 
or no acrolein, instead of continuing with their plan to quit, and any continued tobacco use 
would be far more harmful and risky than completely quitting. (And of course this is 
complicated by the fact that § 904(d) requires disclosures relating to all reported HPHCs, not 
just acrolein.)
Thus, the HPHC disclosures required by § 904(d), to avoid being misleading, should fully 
and fairly address the overall health pros and cons of switching from one brand or type of 
tobacco product to another, especially if switching occurs rather than quitting entirely. 
Furthermore, as with the “understandable” requirement discussed above, any FDA 
determination as to whether a specific HPHC disclosure scheme would be “misleading” (or 
“not misleading”) should be based on an analysis of whether it would prompt a significant 
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number of consumers to change their behavior in ways that either produce no health benefits 
or increase overall health harms and risks.
C. “Lay Person”
Black’s Law Dictionary defines a “lay person” as one who is “not trained in or knowing 
much about a particular profession or subject; not expert, esp[ecially] with reference to law 
or medicine; nonprofessional.” 57 It appears that FDA regulations and case law use the term 
“lay person” sparingly, and it usually refers to someone who is not a health professional. 
However, in FDA-related (non-tobacco) litigation, “lay person” has on occasion been used 
interchangeably with the phrase “ordinary consumer.” 58
The concept of “lay person,” in most legal contexts, does not necessarily reflect 
consideration for those who have low levels of literacy or comprehension. But interestingly, 
the regulation detailing labeling requirements for over-the-counter (OTC) drugs requires 
warnings relating to unsafe use and side effects to be presented “in such terms as render 
them likely to be read and understood by the ordinary individual, including individuals of 
low comprehension, under customary conditions of purchase and use.” 59 This regulation 
implements a statutory requirement for OTC labeling to be “understood by the ordinary 
individual” (which is comparable to “understandable to a lay person”)—but the statute itself 
says nothing about individuals of low comprehension. It appears that the FDA added 
consideration of low-comprehension individuals to the OTC regulation without any further 
statutory hook, which suggests that the agency could do the same for HPHC disclosures. 60
More generally, this example suggests that the FDA’s actions should also take into account 
those with lower levels of literacy, numeracy, or cognitive function (that may adversely 
affect comprehension), non-native English speakers, or other populations that might respond 
differently to the presentation of HPHC information. 61 In the tobacco context, it is also 
particularly important that the FDA consider youth as a potential audience. As the TCA 
itself says, “Virtually all new users of tobacco products are under the minimum legal age to 
purchase such products.” 62 According to the 2012 Surgeon General’s Report, 88% of daily 
cigarette smokers began smoking before reaching the age of 18, often as 12-, or 13-, or 14-
year-olds. 63 Thus, in order to have a meaningful impact on youth tobacco use, the FDA 
should consider how its communications would likely influence adolescents—and even 
younger children—when determining how to implement § 904(d).
To summarize the discussion presented above, the following chart presents (somewhat 
simplified) definitions of “understandable,” “not misleading,” and “lay person” that could be 
used to inform both research and FDA regulatory decisions relating to HPHC disclosures.
II. USING LAW TO INFORM BEHAVIORAL RESEARCH: TESTING 
CONSTITUENT DISCLOSURE OPTIONS
Researchers at UNC and OSU used the legal review outlined above to inform studies of 
consumer responses to different options for presenting information about HPHCs. In 
accordance with FDA’s previous work to develop a website to implement § 904(d), 64 the 
research team believed that the constituent information would be most efficiently presented 
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through a website, and they conducted a series of experiments that manipulated webpage 
design features. 65 Participants evaluated static versions of potential webpages, which varied 
in overall layout look and feel, the number of constituents presented, the format used to 
communicate the health effects of the constituents, the format used to present quantity of 
constituents, and the use of a visual risk indicator. Participants then answered questions 
about the webpage they saw. The full design of these experiments is described elsewhere. 66
To examine the understandability of the disclosures, researchers asked questions—based on 
the definition in Figure 2—designed to examine whether study participants could read, 
comprehend, and appreciate the significance (or lack thereof) of the constituent information 
presented. For example, items designed to evaluate whether the participants could 
understand the constituent information presented included:
• Does cigarette smoke contain [specific constituent]? (Possible responses: yes, no, 
don’t know)
• Does smoking cause [specific health effect]? (Possible responses: yes, no, don’t 
know)
• This webpage clearly shows whether the amount of each chemical is harmful. (5 
possible responses ranging from strongly agree to strongly disagree)
As suggested by these items, the challenge inherent in designing understandable HPHC 
disclosures is in determining what information the public needs to learn from the webpage. 
Is it awareness of the names of chemicals, the resulting health effects, chemical quantities, or 
something more fundamental? Certainly, an important fact for viewers to understand is that 
constituent information—whether the amount of a given constituent or the overall number of 
HPHCs present—cannot be used to determine whether some brands or subbrands of 
cigarettes (or other tobacco products) are less harmful than others. As it is natural for 
consumers to compare brands on the relevant amount of constituents and to (perhaps even 
unconsciously) make judgments about safety based on this information, this will be a major 
challenge for the FDA. 67
Also based on the legal review, in designing survey questions to test whether disclosures are 
“not misleading,” the research team selected questions that focus on the overall impression 
taken away by the viewer. For example, survey items included:
• It’s much safer to smoke cigarettes with fewer chemicals. (5 possible responses 
ranging from strongly agree to strongly disagree)
• If you can’t quit, you should switch to brands/styles with fewer chemicals. (5 
possible responses ranging from strongly agree to strongly disagree)
• A cigarette is much safer to smoke if it has a third less [specific constituent] than 
other cigarettes. (5 possible responses ranging from strongly agree to strongly 
disagree)
• If a website had information like this for all cigarette brands, I would use it to see 
which cigarettes are safer than others. (5 possible responses ranging from 
strongly agree to strongly disagree)
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These survey items focus on ensuring that the viewer is not left with misleading impressions, 
i.e., that the viewer does not draw unsupported conclusions from the information presented. 
Somewhat oddly, this means that in order to show that the HPHC information is not 
misleading, studies must find that such information does not help people to make health-
related decisions about the relative harm of different brands/subbrands of cigarettes. Because 
no currently available brand or subbrand of cigarette is significantly more or less harmful 
and risky than another, 68 the only consumer response to the provided HPHC information 
that indicates a lack of being misled is a conclusion that there are no meaningful differences 
between brands and thus one must quit smoking to secure significant health benefits. 69
This desired response is problematic, however, because psychological theory and research 
suggest that people expect that information provided to them is intended to be useful.70 This 
includes the expectation that information is designed to be truthful, relevant, and 
understandable. If consumers are presented with brand and subbrand information, they may 
rightfully expect that all of this information must be important and not redundant. They are 
likely to assume that important differences therefore must exist between brands/subbrands, 
or the FDA would not provide this information. Thus, the very nature of the communication 
may be misleading, when viewed through the lens of psychological theory, given that study 
participants are supposed to conclude that brand/subbrand differences are not meaningful in 
terms of their impact on health.
It is important to emphasize one uncommon feature of the research approach taken here: use 
of an in-depth legal review to inform the design of a research study. Although the FDA 
considers the relevant statutory framework and the advice of its own attorneys when making 
regulatory decisions, it is rare for researchers to incorporate legal research directly into the 
design of their research studies. Doing so, however, has at least two important advantages. 
For one, it helps to ensure that the resulting research can directly inform the FDA’s decision-
making process. Too often, researchers conduct their studies without a nuanced awareness of 
the relevant legal framework, and as a result, the research (though perhaps scientifically 
valuable) is of limited utility to policymakers. Although we have decades of research on 
whether people have heard of some cigarette smoke constituents, little of the information 
was gathered in such a way that it can inform FDA decisions. 71 Secondly, such an approach 
makes it more likely that the FDA’s regulatory decisions, if based on the resulting research, 
can withstand potential legal challenges. The FDA will be able to demonstrate that its 
decisions were guided by a careful analysis of which HPHC disclosure formats are 
“understandable and not misleading to a lay person,” based on research into how regulatory 
agencies and the courts have previously understood those terms. 72
III. POLICY CONSIDERATIONS AND RECOMMENDATIONS
The FDA finds itself in a difficult position due to the two separate requirements of § 904(d): 
(1) to publish a listing of HPHC information, by brand and subbrand, and (2) to ensure that 
the list is “understandable and not misleading to a lay person.” As suggested above, given 
the limited utility of HPHC information for lay people, it is not clear that the FDA will ever 
be able to meet the latter requirement. It may be that any presentation of constituent 
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information by brand and subbrand inevitably produces confusion and inaccurate 
impressions of relative harm.
If that is the case, what should the FDA do? Publishing the information in a way that is 
misleading would contradict the statute and also run counter to the general goals of the TCA 
(reducing the public health harms caused by tobacco use and better informing consumers 
about tobacco product health consequences). At the same time, however, the statute says that 
the FDA “shall publish” HPHC information. Indeed, it provides the FDA with a deadline to 
do so that has already passed: “not later than 3 years after the date of enactment of the 
[TCA].” 73 Ignoring this statutory mandate entirely is not an attractive option, as it would 
both set a troublesome precedent74 and open up the FDA to a potential mandamus lawsuit. 
75
 FDA could try to defend itself in any such lawsuit by showing that, despite its good faith 
efforts, it has been unable to develop a way to disclose the required information in a manner 
that would not be misleading to laypersons and would not risk serious adverse public health 
consequences. But it is likely that the courts would still require the FDA to comply with the 
disclosure requirement to the extent it could do so without misleading consumers in ways 
that would likely cause public health harms. Additionally, even if potentially misleading to 
some members of the public, disclosure of the constituent information (and ingredient 
information more generally) could be valuable to tobacco control researchers, and could 
spur the development of new research that would inform other possible FDA efforts to 
prevent and reduce tobacco-related harms. 76
Thus, to comply with § 904(d) the FDA must “publish” at least some HPHC data in some 
“format.” Returning to the public health goals of the TCA, however, it must still ensure that 
its publication of any such information benefits public health in the aggregate (or, at the very 
least, does not harm public health). Recognizing that the collection of HPHC data and the 
publishing of such data are distinct requirements suggests how the FDA might interpret the 
language of § 904(d) in line with the statute’s overriding purposes:
1. If it is possible for the FDA to publish HPHC information by brand and by 
subbrand in a manner that is “understandable and not misleading to a layperson” 
(as defined above), then it must do so. This will almost certainly require 
providing additional context and clarifying information.
2. If it is not possible to provide such detailed information in a manner that is 
“understandable and not misleading to a layperson,” then the FDA should 
determine what information about HPHCs it can publish in certain formats that 
would be “understandable and not misleading to a layperson,” and publish such 
information accordingly. This might require reporting HPHC levels in a more 
aggregate manner, rather than by brand or subbrand, in addition to adding 
supplemental contextual information. 77 At the same time, the FDA could make 
more detailed brand and subbrand information available upon request for 
confidential research and other appropriate purposes, so as to facilitate research 
and transparency without undermining the TCA’s public health goals.
The second option could be defended against any potential legal challenge by noting that the 
law gives the FDA flexibility to determine the “manner” of the HPHC data publication, and 
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that releasing data in a way that is not understandable or is misleading would plainly violate 
the statute’s requirements. If pursuing this option, the FDA should issue a formal notice that 
explains how it is interpreting and applying the language of § 904(d) to promote the core 
goals of the TCA most effectively, thereby putting its interpretation in the strongest possible 
position to withstand any legal challenges. 78
Two additional policy considerations merit mention. First, even though § 904(d) focuses 
only on the disclosure of HPHC information, the FDA has broad authority to educate the 
public about the harms of tobacco use. Placing the HPHC disclosures within this broader 
context may help to minimize any potentially adverse effects of publishing the information.
Secondly, although the FDA should make its best effort to comply with the requirements of 
§ 904(d), it should also be mindful of the allocation of its resources. If it appears from 
ongoing research that disclosure of HPHC is unlikely to produce significant public health 
gains (in whatever form presented), then the FDA should not devote too much more time and 
research funding to this provision of the TCA. Although additional research may help make 
a disclosure website incrementally more effective, the cost may not be worth the effort if the 
public health benefits are likely to be negligible in any event. Given its limited resources, the 
FDA should prioritize research and regulatory efforts most likely to further its core mission 
of reducing the public health harms of tobacco use.
CONCLUSION
Though it appears logical that disclosing more information about the levels of harmful and 
potentially harmful constituents in different tobacco products would lead to improved 
health-related decision making, that is not necessarily what happens in practice. 79 Thus, the 
FDA should ensure that in implementing § 904(d)’s requirement to provide constituent 
information in a manner that is “understandable and not misleading to a layperson,” it 
interprets those terms in a manner that does not contradict or impede the TCA’s primary 
purpose of reducing death and disease caused by tobacco use. The legal review outlined in 
this paper is intended to support the FDA’s effort to do so. If it is impossible to deliver 
detailed HPHC information to the public in a manner that is “understandable and not 
misleading,” the FDA should exercise its discretion to limit the amount of information 
presented.
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Figure 1. 
Abbreviated List of Harmful and Potentially Harmful Constituents that Manufacturers Must 
Report to the FDA1
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Figure 2. 
Defining “Understandable,” “Not Misleading,” and “Lay Person” in § 904(d)
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